- Home
- LFCR vs DRTS Comparison
LFCR vs DRTS Comparison
Compare LFCR & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFCR
- DRTS
- Stock Information
- Founded
- LFCR 1986
- DRTS 2015
- Country
- LFCR United States
- DRTS Israel
- Employees
- LFCR N/A
- DRTS N/A
- Industry
- LFCR Biotechnology: Pharmaceutical Preparations
- DRTS Medical/Dental Instruments
- Sector
- LFCR Health Care
- DRTS Health Care
- Exchange
- LFCR Nasdaq
- DRTS Nasdaq
- Market Cap
- LFCR 308.8M
- DRTS 300.2M
- IPO Year
- LFCR N/A
- DRTS N/A
- Fundamental
- Price
- LFCR $7.21
- DRTS $3.77
- Analyst Decision
- LFCR Buy
- DRTS Strong Buy
- Analyst Count
- LFCR 4
- DRTS 1
- Target Price
- LFCR $8.00
- DRTS $9.00
- AVG Volume (30 Days)
- LFCR 110.8K
- DRTS 64.5K
- Earning Date
- LFCR 10-03-2025
- DRTS 08-11-2025
- Dividend Yield
- LFCR N/A
- DRTS N/A
- EPS Growth
- LFCR N/A
- DRTS N/A
- EPS
- LFCR N/A
- DRTS N/A
- Revenue
- LFCR $128,867,000.00
- DRTS N/A
- Revenue This Year
- LFCR $4.78
- DRTS N/A
- Revenue Next Year
- LFCR $12.02
- DRTS N/A
- P/E Ratio
- LFCR N/A
- DRTS N/A
- Revenue Growth
- LFCR 0.47
- DRTS N/A
- 52 Week Low
- LFCR $4.33
- DRTS $2.11
- 52 Week High
- LFCR $8.85
- DRTS $4.39
- Technical
- Relative Strength Index (RSI)
- LFCR 43.53
- DRTS 70.34
- Support Level
- LFCR $7.37
- DRTS $3.35
- Resistance Level
- LFCR $8.69
- DRTS $3.63
- Average True Range (ATR)
- LFCR 0.36
- DRTS 0.14
- MACD
- LFCR -0.02
- DRTS 0.04
- Stochastic Oscillator
- LFCR 11.38
- DRTS 98.67
About LFCR Lifecore Biomedical Inc.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.